Single-cell optical window imaging in CDK1-FRET biosensor mice to assess tissue stiffness and optimise delivery and therapeutic response to Gemcitabine/Abraxane in pancreatic cancer.

CDK1-FRET 生物传感器小鼠的单细胞光学窗口成像可评估胰腺癌中的组织硬度并优化吉西他滨/Abraxane 的递送和治疗反应。

• 批准号: nhmrc : GNT1105640
• 负责人: A/Pr Paul Timpson
• 金额: $ 67.7万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/single-cell-optical-pancreatic-cancer/1346450
• 关键词: Single; cell; optical; window; imaging

Inefficient drug response in solid tumour tissue is commonly a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we have mapped areas of poor drug response within distinct regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug targeting in order to improve the encouraging anti-cancer profile of the new drug combination Gemcitabine/Abraxane in pancreatic cancer.

实体瘤组织中的无效药物反应通常是癌症治疗临床有效性的限制因素。利用尖端的成像技术和模拟疾病的3D模型，我们绘制了肿瘤不同区域内药物反应不良的区域。在这里，我们精确定位并专门针对限制有效药物靶向的关键因素，以改善新型药物组合吉西他滨/Abraxane在胰腺癌中令人鼓舞的抗癌作用。